We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Management of mild hidradenitis suppurativa: our greatest challenge yet.
- Authors
van der Zee, H.H.; van de Bunte, M.; van Straalen, K.R.
- Abstract
Therefore, providing patients with mild HS with scientifically proven effective treatments will require a different way of thinking about outcome measures and treatment targets. Hidradenitis suppurativa (HS) is a debilitating, chronic, inflammatory disease originating from hair follicles.1 When thinking of this disease, images of a patient with extensive tunnel formation and continuous foul-smelling drainage spring to mind. These images have been the driving force behind increasing scientific interest in this disease over the past 10 years, resulting in one approved biologic (adalimumab) and multiple ongoing clinical trials for patients with moderate-to-severe disease.
- Subjects
HIDRADENITIS suppurativa; PREVENTIVE medicine
- Publication
British Journal of Dermatology, 2022, Vol 186, Issue 2, p355
- ISSN
0007-0963
- Publication type
Article
- DOI
10.1111/bjd.20780